1,720,981 research outputs found
Do Socioeconomic Inequalities Impact The Social Cost Of Chronic Kidney Disease In Italy?
No full textThe economic evaluation of bone-anchored hearing aids (Bahas): A systematic literature review
No full textEconomic Impact of Employment Status on The Social Cost of Morbid Obese Patients Submitted to Bariatric Surgery
No full text
The impact of cardiovascular disease and type 2 diabetes mellitus on social cost in chronic kidney disease patients in Italy
No full textOBJECTIVES: Chronic kidney disease (CKD) is leading condition of several comorbidities with additional social economic burden. The study aims to estimate the economic impact of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) on the social cost of a patient with CKD (stage IV and V pre-dialyses) in Italy. METHODS: All adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region have been enrolled during 7 weeks in the cross sectional study. Direct medical costs have been estimated using tariffs for laboratory test, diagnostic exams, visits and hospitalization and price for drugs. Non medical costs included the cost of diet, patients and caregivers travel expenses, domestic help and informal care. The loss of productivity of patients and caregivers have been estimated as indirect costs using the human capital approach. The incremental effects of having comorbidities on social cost of CKD were estimated by multivariate Generalized Linear Models (log link, Gamma family) adjusting for gender, age and stage of CKD. Costs are expressed in Euro 2012. RESULTS: Among 484 CKD patients enrolled, CVD and T2DM have been found respectively in 214 (44%) and 171 (35%) patients. The raw estimated mean annual social costs were €11,375 (± €7,480) per patient with CKD-CVD and €11,627 (± €7,657) per patient with CKD-T2DM. Direct non medical costs and indirect costs accounted respectively for 31% and 23% of social cost for CKD-CVD and 30% and 22% for CKD-T2DM. The incremental effects of having comorbidities on the overall social cost of CKD were €2,928 (95% CI: €1,680-€4,176, p=0.000) for CVD and €2,640 (95% CI: €1,301-€3,979, p=0.000) for T2DM. CONCLUSIONS: CVD and T2DM significantly increase the social cost of CKD due to the rise of the medical component. However the burden of the disease is mainly sustained by patients, their families and the productivity system
The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise
No full textThe objective of this study is to estimate the mean annual social cost per adult person and the total social cost of rheumatoid arthritis (RA) in Italy. A literature review was performed by searching primary economic studies on adults in order to collect cost data of RA in Italy in the last decade. The review results were merged with data of institutional sources for estimating - following the methodological steps of the cost of illness analysis - the social cost of RA in Italy. The mean annual social cost of RA was € 13,595 per adult patient in Italy. Affecting 259,795 persons, RA determines a social cost of € 3.5 billions in Italy. Non-medical direct cost and indirect cost represent the main cost items (48% and 31%) of the total social cost of RA in Italy. Based on these results, it appears evident that the assessment of the economic burden of RA solely based on direct medical costs evaluation gives a limited view of the phenomenon
Systematic review of the scientific literature on the economic evaluation of cochlear implants in adult patients
No full textSystematic review of the scientific literature on the economic evaluation of cochlear implants in paediatric patients
No full textCochlear implant in prelingual deafened oralist adults: Speech perception outcome, subjective benefits and quality of life improvement
No full textSocial costs of different procedures in bariatric surgery in patients with obesity-related comorbidities
No full textOBJECTIVES: To estimate the social cost of bariatric surgery techniques in obese patients with hypertension, diabetes mellitus (T2DM) and anxiety-depression disorders (ADD). METHODS: A longitudinal multicenter study was conducted by enrolling obese adult patients in charge to 6 Hospitals in Italy at time of intervention of gastric banding, gastric by-pass, and sleeve gastrectomy and following up to 1 year. Direct medical costs were estimated using tariffs for laboratory tests, diagnostic exams, visits, and prices for drugs. Procedure and inpatient cost data were collected at Center level. Non medical costs included costs for travel and accommodation, domestic help and informal care. The loss of productivity of patients have been estimated using the human capital approach. The incremental effects of having comorbidities on social costs were estimated by multivariate Generalized Linear Models (log link, Gamma family) adjusting for gender, age, BMI, type of intervention and complications. Costs are expressed in Euro 2013. RESULTS: Among 301 patients enrolled, 108 (36%) had hypertension, 53 (18%) T2DM and 47 (16%) ADD. The raw social cost of intervention were €8,749 (± €2,359), €9,511 (± €2,292) and €8,999 (± €2,275) for patients with hypertension, T2DM and ADD. A significant incremental effect of having T2DM was found on social cost of intervention (€751, 95%CI: 242-1,259, p=0.004). 1 year after intervention reductions of 48%, 81% and 15% were observed for hypertension, T2DM and ADD. The raw social annual costs estimated were € 2,461 (± € 1,490) for hypertension, € 2,424 (± € 951) for T2DM and € 3,582 (± € 2,017) for ADD. Direct non medical costs and indirect costs represent the main component of social cost in patients with hypertension and ADD. CONCLUSIONS: Bariatric surgery led to a reduction of obesity-related comorbidities. One year after, the economic burden is mainly sustained by patients, their families and the productivity system
- …
